Table 2.
Effect of anti-CD40 treatment on MHV-68-specific cytolytic activity in spleen and BAL of MHC Class II −/− mice
| Mice | Treatment | % Specific
lysis
|
n | ||
|---|---|---|---|---|---|
| BAL
|
Spleen
|
||||
| 10∶1* | 2.5∶1* | 50∶1* | |||
| −/− | Control | 31.0 ± 15.0 | 19.3 ± 15.4 | 26.3 ± 10.4 | 4 |
| −/− | Anti-CD40 | 25.0 ± 3.1 | 14.0 ± 2.4 | 25.0 ± 10.0 | 4 |
| +/+ | None | 43.0 | 14.0 | 25 | 1† |
MHC Class II −/− or +/+ mice were infected with MHV-68 and treated with anti-CD40 or control antibody as described in the legend to Table 1. BAL and spleen cells harvested 60 days after infection were tested for virus-specific CTL activity in a chromium release assay using MHV-68-infected MEF-1 cells as targets. Data are expressed as mean percent specific lysis ± SD, for the effector to target (E∶T) ratios specified. n, number of mice tested.
*
E∶T ratio.
†
Cells from two wild-type mice were pooled for CTL assays.